Meeting
2016 ASCO Annual Meeting
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC).
Authors
Funda Meric-Bernstam
Department of Investigational Cancer Therapeutics (Phase 1 Program), Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Funda Meric-Bernstam , Nizar M. Tannir , James Walter Mier , Angela DeMichele , Melinda L. Telli , Alice C. Fan , Pamela N. Munster , Richard D. Carvajal , Keith W. Orford , Mark K. Bennett , Othon Iliopoulos , Taofeek Kunle Owonikoko , Manish R. Patel , Rana McKay , Jeffrey R. Infante , Martin Henner Voss , James J. Harding
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02071862
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4568)
DOI
10.1200/JCO.2016.34.15_suppl.4568
Abstract #
4568
Poster Bd #
190
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).
First Author: Nizar M. Tannir
Poster
2012 ASCO Annual Meeting
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study.
First Author: Igor Puzanov
Poster
2019 Genitourinary Cancers Symposium
CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.
First Author: Funda Meric-Bernstam
Poster
2016 ASCO Annual Meeting
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).
First Author: Angela DeMichele